Novartis: a child died in Russia while treating SMA with Zolgensma

This is reported by RIA Novosti with reference to a statement by the Swiss drug manufacturer Novartis.

It is clarified that deaths were recorded due to acute liver failure that occurred after five to six weeks of drug administration.

Earlier it became known that the drug "Zolgensma" used to treat spinal muscular atrophy officially appeared in Russia. 

The Commissioner for Children's Rights in Tatarstan, Irina Volynets, in an interview with RT, commented on the official appearance in Russia of the drug Zolgensma for the treatment of spinal muscular atrophy.